정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 240 | Not yet recruiting | the Investigation Into Beneficial Effects of High-dose Interferon Beta 1-a, Compared to Low-dose Interferon Beta 1-a in Moderate to Severe Covid-19 | Covid19 | Drug: High dose Interferon-beta 1a Drug: Lopinavir/Ritonavir Drug: Low dose Interferon-beta 1a |
Phase 2 | Shahid Beheshti University of Medical Sciences | OTHER | 100 | All | 18 Years ~ 100 Years | |
| 239 | Not yet recruiting | The LEAD COVID-19 Trial: Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations | Disseminated Intravascular Coagulation | Drug: Aspirin 81 mg Dietary Supplement: Vitamin D |
Phase 2 | Louisiana State University Health Sciences Center in New Orleans | OTHER | 1080 | All | 18 Years | |
| 238 | Recruiting | The MEseNchymal coviD-19 Trial: MSCs in Adults With Respiratory Failure Due to COVID-19 or Another Underlying Cause | Acute Respiratory Distress Syndrome | Biological: CYP-001 | Phase 2 | Cynata Therapeutics Limited, Cerebral Palsy Alliance | INDUSTRY | 24 | All | 18 Years | Nepean Hospital, Kingswood, New South Wales, Australia Westmead Hospital, Westmead, New South Wales, Australia Footscray Hospital, Footscray, Victoria, Australia Sunshine Hospital, Saint Albans, Victoria, Australia |
| 237 | Recruiting | The MONACO Cell Therapy Study: Monocytes as an Anti-fibrotic Treatment After COVID-19 | Covid19 | Biological: MON002 | Phase 2 | Guy's and St Thomas' NHS Foundation Trust, King's College London | OTHER | 5 | All | 18 Years | Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom |
| 236 | Completed | The Nitazoxanide Plus Atazanavir for COVID-19 Study | Covid-19 | Drug: Nitazoxanide and atazanavir/ritonavir Other: Standard of Care |
Phase 2 | Obafemi Awolowo University, University of Liverpool, African Centre of Excellence for Genomics of Infectious Diseases, Infectious Disease Hospital Olodo, Obafemi Awolowo University Teaching Hospitals Complex, Osun State Ministry of Health, Olabisi Onabanjo University Teaching Hospital | OTHER | 57 | All | 18 Years ~ 75 Years | Olabisi Onabanjo University Teaching Hospital, Sagamu, Ogun State, Nigeria Infectious Disease Hospital, Olodo, Ibadan, Oyo State, Nigeria |
| 235 | Terminated | The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine) | COVID-19 | Drug: Hydroxychloroquine Sulfate 400 mg twice a day Drug: Hydroxychloroquine Sulfate 600 mg twice a day Drug: Hydroxychloroquine Sulfate 600 mg once a day Drug: Placebo oral tablet |
Phase 2 | Ravi Amaravadi, MD | OTHER | 173 | All | 18 Years | University of Pennsylvania, Philadelphia, Pennsylvania, United States |
| 234 | Recruiting | The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19 | COVID-19 | Drug: Clevudine Drug: Placebo |
Phase 2 | Bukwang Pharmaceutical | INDUSTRY | 60 | All | 19 Years | Korea University Guro Hospital, Seoul, Korea, Republic of |